Who is sponsoring NCT05275985?

NCT05275985 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05275985?

Interventions in NCT05275985: 68Ga-FAPI Positron Emission Tomography-Computed Tomography.

Is NCT05275985 still recruiting?

NCT05275985 is currently status unknown. Last updated 11 March 2022.

Last reviewed 2022-03-11 · How we verify

NCT05275985

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma

Status unknown NA Last updated 11 March 2022

What this trial tests

NA trial testing 68Ga-FAPI Positron Emission Tomography-Computed Tomography in PDAC in 80 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
30 November 2022

1 June 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	80
Start date	1 March 2022
Primary completion	30 November 2022
Estimated completion	1 June 2023
Sites	1 location across China

Drugs / interventions tested

68Ga-FAPI Positron Emission Tomography-Computed Tomography

Conditions studied

PDAC — all drugs for PDAC →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 80, any sex, with PDAC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitutes a major proportion of cells within the tumor microenvironment, especially in primary pancreatic ductal carcinoma (PDAC). In this prospective study, we aimed to evaluate the performance and value of 68Ga-FAPI-04 PET/CT in the patients with PDAC.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.
Zhang Z, Tao J, Qiu J, Cao Z, et al · · 2024 · cited 21× · PMID 37726505 · DOI 10.1007/s13402-023-00872-z
Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging.
Saúde-Conde R, Arçay Öztürk A, Stosic K, Azurmendi Senar O, et al · · 2024 · cited 13× · PMID 38540204 · DOI 10.3390/biomedicines12030591
Comparison of early and late <sup>68</sup>Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas.
Hoppner J, van Genabith L, Hielscher T, Heger U, et al · · 2023 · cited 13× · PMID 37857656 · DOI 10.1038/s41598-023-43049-2
Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.
Wu Y, Wang X, Sun X, Gao X, et al · · 2025 · cited 7× · PMID 41049753 · DOI 10.1016/j.apsb.2025.07.009
Cancer-Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy.
Fan C, Zhu W, Chen Y, Zhu W, et al · · 2025 · cited 4× · PMID 41164803 · DOI 10.1002/mco2.70415

Verify or expand the search:

Other recruiting trials for PDAC

Currently open trials in the same condition.

NCT07441174 — IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli · Phase 1, PHASE2 · recruiting
NCT07252232 — Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 3 · recruiting
NCT07145450 — Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With · Phase 1, PHASE2 · recruiting
NCT06515587 — Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer · NA · recruiting
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05275985 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 11 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05275985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing